TY - JOUR
T1 - Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironment
AU - Abooali, Maryam
AU - Schlichtner, Stephanie
AU - Lei, Xi
AU - Aliu, Nijas
AU - Ruggiero, Sabrina
AU - Loges, Sonia
AU - Ziegler, Martin
AU - Hertel, Franziska
AU - Volckmar, Anna-Lena
AU - Stenzinger, Albrecht
AU - Christopoulos, Petros
AU - Thomas, Michael
AU - Klenova, Elena
AU - Meyer, N Helge
AU - Boussios, Stergios
AU - Heaton, Nigel
AU - Zen, Yoh
AU - Zamalloa, Ane
AU - Chokshi, Shilpa
AU - Urbani, Luca
AU - Richard, Sophie
AU - Kirubendran, Kavitha
AU - Hussain, Rohanah
AU - Siligardi, Giuliano
AU - Cholewa, Dietmar
AU - Berger, Steffen M
AU - Yasinska, Inna M
AU - Fasler-Kan, Elizaveta
AU - Sumbayev, Vadim V
N1 - Copyright © 2025 The Author(s). Published by Elsevier B.V. All rights reserved.
PY - 2025/4/28
Y1 - 2025/4/28
N2 - V-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of VISTA activity and functions by factors of tumour microenvironment (TME) remain unclear and understanding these processes is required in order to develop successful personalised cancer immunotherapeutic strategies and approaches. Here we report for the very first time that VISTA interacts with another immune checkpoint protein galectin-9 inside the cell most likely facilitating its interaction with TGF-β-activated kinase 1 (TAK1). This process is required for protection of lysosomes, which is crucial for many cell types and tissues. We found that VISTA expression can be differentially controlled by crucial factors present in TME, such as transforming growth factor beta type 1 (TGF-β) and hypoxia as well as other factors activating hypoxic signalling. We confirmed that involvement of these important pathways modulated by TME differentially influences VISTA expression in different cell types. These networks include: TGF-β-Smad3 pathway, TAK1 (TGF-β-activated kinase 1) or apoptosis signal-regulating kinase 1 (ASK1)-induced activation of activating transcription factor 2 (ATF-2) and hypoxic signalling pathway. Based on this work we determined the five critical functions of VISTA and the role of TME factors in controlling (modulating or downregulating) VISTA expression.
AB - V-domain Ig-containing suppressor of T cell activation (VISTA) is a unique immune checkpoint protein, which was reported to display both receptor and ligand activities. However, the mechanisms of regulation of VISTA activity and functions by factors of tumour microenvironment (TME) remain unclear and understanding these processes is required in order to develop successful personalised cancer immunotherapeutic strategies and approaches. Here we report for the very first time that VISTA interacts with another immune checkpoint protein galectin-9 inside the cell most likely facilitating its interaction with TGF-β-activated kinase 1 (TAK1). This process is required for protection of lysosomes, which is crucial for many cell types and tissues. We found that VISTA expression can be differentially controlled by crucial factors present in TME, such as transforming growth factor beta type 1 (TGF-β) and hypoxia as well as other factors activating hypoxic signalling. We confirmed that involvement of these important pathways modulated by TME differentially influences VISTA expression in different cell types. These networks include: TGF-β-Smad3 pathway, TAK1 (TGF-β-activated kinase 1) or apoptosis signal-regulating kinase 1 (ASK1)-induced activation of activating transcription factor 2 (ATF-2) and hypoxic signalling pathway. Based on this work we determined the five critical functions of VISTA and the role of TME factors in controlling (modulating or downregulating) VISTA expression.
KW - Tumor Microenvironment/immunology
KW - Humans
KW - MAP Kinase Kinase Kinases/metabolism
KW - B7 Antigens/metabolism
KW - Signal Transduction
KW - Cell Line, Tumor
KW - Neoplasms/immunology
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/2831/viewcontent/1_s2.0_S0304383525001454_main.pdf
U2 - 10.1016/j.canlet.2025.217581
DO - 10.1016/j.canlet.2025.217581
M3 - Article
C2 - 39983894
SN - 0304-3835
VL - 616
SP - 217581
JO - Cancer Letters
JF - Cancer Letters
M1 - 217581
ER -